Cost-effectiveness of managing HIV infection

References

• Dixon S, McDonald S, Roberts J. The impact of HIV and AIDS on Africa's economic development. BE Merl 1. 324, 232–234 (2002).
   Google Scholar
• Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 359, 1635–1643 (2002).
   PubMed Web of Science ®Google Scholar
• HIV/AIDS a global economic threat, UN official warns. AIDS Policy Law17, 9 (2002).
   Google Scholar
• Crane J, Quirk K, van der Straten A. "Come back when you're dying:" the commodification of AIDS among California's urban poor. Soc. Sc]. Merl 55, 1115–1127 (2002).
   Google Scholar
• Benatar SR The HIV/AIDS pandemic: a sign of instability in a complex global system.' Med. Philos. 27, 163–177 (2002).
   Google Scholar
• John i M, David Paltiel A, Goldie SJ, Freedberg IKA. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care 40, 429–441 (2002).
   Google Scholar
• Logie D. Global voices on HIV/AIDS. Unfairness of social and economic structures affect AIDS in Africa. BE Med J. 324, 1034 (2002).
   Google Scholar
• Wood E, Montaner JS, Chan K et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS16, 2065–2072 (2002).
   PubMed Web of Science ®Google Scholar
• Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS16, 597–603 (2002).
   PubMed Web of Science ®Google Scholar
• Schrappe M, Lauterbach K. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries. AIDS12 (Suppl A), S231—S238 (1998).
   Google Scholar
• Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society — USA Panel. JAIVIA 288, 222–235 (2002).
   PubMed Web of Science ®Google Scholar
• Mocroft A, Phillips AN, Friis-Moller N et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antiviral Ther. 7, 21–30 (2002).
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl. J. Med. 338, 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Masur H, Holmes KIK. Guidelines for preventing opportunistic infections among HIV-infected persons 2002. Recommendations of the US Public Health Service and the IDSA. MMWR 51 (RR-8), 1–52 (2002).
   Google Scholar
• Stoll M, Claes C, Schulte E, Graf von der Schulenburg JM, Schmidt RE. Direct costs for the treatment of HIV-Infection in a German cohort after the introduction of HAART. Eur J. Med Res. 7,463–471 (2002).
   Google Scholar
• •German cost-of-illness study. Direct costs decreased despite increasing use of antirerovirals and increasing drug dispending prices.
   Google Scholar
• Keiser P, Kvanli MB, Turner D et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J. Acquit: Immune Defic. Synth: Hum. Retmviml. 20, 28–33 (1999).
   Google Scholar
• •Although antiretrovirals drugs are expensive, they save substantially more than they cost by avoiding hospitalization.
   Google Scholar
• Blankson JN, Persaud D, Siliciano RE The challenge of viral reservoirs in HIV-1 infection. Ann. Rev Med53, 557–593 (2002).
   Google Scholar
• Weinstein MC, Goldie SJ, Losina E et al. Of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Int. Med. 134 (6), 440–450 (2001).
   Google Scholar
• Ho DD. Time to hit HIV, early and hard. N. Engl. J. Med 333, 450–451 (1995).
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119–129 (2002).
   PubMed Web of Science ®Google Scholar
• ••Actual multicenter study to clinicaloutcomes under highly active antiretroviral therapy (HAART) in clinical reality
   Google Scholar
• Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS17, 711–720 (2003).
   Google Scholar
• Hogg RS, Yip B, Chan KJ, Wood E et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286, 2568–2577, (2001).
   PubMed Web of Science ®Google Scholar
• •European guidelines for the treatment of HIV-infected individuals.
   Google Scholar
• Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD, HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS16, 1617–1626 (2002).
   Google Scholar
• ••Large cohort study allows defining thequestion, what does long term treatment with HAART mean? After a period of less than 1 year, half of the patients had changed their initial treatment.
   Google Scholar
• Law M, Friis-Moller N, Weber R et al DAD Study Group. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 4(1), 1–10 (2003).
   Google Scholar
• Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS15, 1369–1377 (2001).
   Google Scholar
• ••Meta-analysis of clinical studies inantiretroviral naive subjects. Conclusion: less pill burden is more effective in long-term success.
   Google Scholar
• Paterson DL, Swindells S, Mohr J et al Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Int. Med 133, 21–30 (2000).
   PubMed Web of Science ®Google Scholar
• •• Compliance/adherence predicts success of antiretroviral therapy. In this study compliance of less than 95% was associated with an increase in virologic failure. Compliance below 70% resulted in failing to control the virus in most cases.
   Google Scholar
• Phillips AN, Miller V, Sabin C et al Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 15 (18), 2379–2384 (2001).
   Google Scholar
• Moore RD. Cost effectiveness of combination HIV therapy: 3 years later.PharmacoEconomics 17, 325–330 (2000).
   Google Scholar
• Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. PhatmacoEconomics 10, 109–113 (1996).
   PubMed Web of Science ®Google Scholar
• •Economic evaluation.
   Google Scholar
• Sendi PP, Bucher HC, Harr T et al Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS'13, 1115–1122 (1999).
   Google Scholar
• •Economic evaluation.
   Google Scholar
• Cook J, Dasbach E, Coplan P et al Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res. Hum. Retroviruses 15, 499–508 (1999).
   PubMed Web of Science ®Google Scholar
• •Economic evaluation.
   Google Scholar
• Anis AH, Guh D, Hogg RS et al The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. PharmacoEconomics 18, 394–404 (2000).
   Google Scholar
• •Economic evaluation.
   Google Scholar
• Caro JJ, O'Brien JA, Migliaccio-Walle K et al Economic analysis of initial HIV treatment: efavirenz-versus indinavir-containing triple therapy. PharmacoEconomics 19, 95–104 (2001).
   Google Scholar
• •Economic evaluation.
   Google Scholar
• Freedberg KA, Losina E, Weinstein MC et al The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl. J. Med 344, 824–831 (2001).
   PubMed Web of Science ®Google Scholar
• •Economic evaluation.
   Google Scholar
• Parker R. The global HIV/AIDS pandemic, structural inequalities and the politics of international health. Am. j Public Health. 92, 343–346 (2002).
   PubMed Web of Science ®Google Scholar
• Schuldenk U, Ashcroft RE. Affordable access to essential medication in developing countries: conflicts between ethical and economic imperatives. j Med. Philos. 27, 179–195 (2002).
   Google Scholar
• Bergstrom TC. When is a man's life worth more than his human capital? In: The Value of Life and Safe Jones-Lee MW (Ed.). North-Holland Publishing Company, Amsterdam, The Netherlands, 3–26 (1982).
   Google Scholar
• Stoll M, Claes C, Schulte E, Schulenburg JM, Schmidt RE. The HIV infection as subject of health-economic analyses (in German). Jaeger H (Ed.). AIDS and HIV-Infection, diagnostics, clinic, treatment. Manual and atlas for clinic and practice. Ecomed. Munich IX — 3.2, 1–27 (2002). 101 UNAIDS: AIDS epidemic update, December (2003) www.unaids.org (Accessed January 2004).
   Google Scholar
• ••Source with international epidemiological data.
   Google Scholar
• Hoffmann C, Kamps BS (Eds). HIV Medicine 2003. Flying Publisher (2003). http://hivmedicine.com (Accessed January 2004).
   Google Scholar
• ••Medical textbook that provides acomprehensive and overview of the treatment of the HIV infection (regularly updated).
   Google Scholar
• German AIDS-society (DAIG) and Austrian AIDS-society (OEAG): Antiretroviral therapy of HIV infection. German—Austrian guidelines (July 2002) wwwski.de/INFEKT/AIDS_STD/ BR LINIE/BR_LINIE.HTM (Accessed January 2004)
   Google Scholar
• •German/Austrian guidelines for treatment of the HIV-infected.
   Google Scholar
• Data according to German pharmaceutical retail prices. www.gelbe-liste.de (Accessed January 2004)
   Google Scholar
• Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DIII IS) . Guidelines for the Use ofAntiretroviral Agents in HIV-1-Infected Adults and Adolescents (July 14, 2003). http://aidsinfo.nih.gov (Accessed January 2004)
   Google Scholar
• •US antiretroviral treatment guideline.
   Google Scholar
• Clumeck N, European Aids Clinical Society (EACS). EUROGUIDELINES. European Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe 2001. www.eacs.ws/download/ European_Treatment_Guidelines.pdf (Accessed January 2004). Affiliations
   Google Scholar